Gilead's Livdelzi (Seladelpar) Shows Sustained Efficacy And Long-Term Safety In Primary Biliary Cholangitis; 81% Achieve Biochemical Response By Month 30, 41% Reach ALP Normalization, And 27% Experience Near Resolution Of Itch In Phase 3 ASSURE Study

Benzinga11/16 00:01

Investors Await BOE Verdict on Whether Budget Hinders Rate Cuts

BNN Bloomberg11/04 13:00

Li Bang International Corporation Inc. Announces Closing of Initial Public Offering

GlobeNewswire10/25 04:30

MassMutual Becomes First U.S. Insurer to Offer Policyowners Free Access to AI-Guided Mental Health Support

Businesswire10/17 21:00

アシュアー ホールディングス | 10-Q：Q2 2024 四半期報告書

SEC09/28 04:59

Delisting of Securities of OceanTech Acquisitions I Corp.; OCA Acquisition Corp.; Assure Holdings Corp.; Selina Hospitality PLC; Maquia Capital Acquisition Corporation; ToughBuilt Industries, Inc.; SunPower Corporation; Meta Materials Inc.; Talis...

GlobeNewswire09/19 04:05